TheraVet SA (ALVET.PA)
EUR 0.11
(-0.46%)
EUR 0.11
(-0.46%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -517.33 Thousand EUR | 7.92% |
| 2022 | -1.39 Million EUR | -60.92% |
| 2021 | -860.41 Thousand EUR | -178.0% |
| 2020 | -317.65 Thousand EUR | -275.83% |
| 2019 | -84.52 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -314.67 Thousand EUR | 0.0% |
| 2024 Q1 | -314.67 Thousand EUR | 15.94% |
| 2023 Q2 | -628.76 Thousand EUR | -98.84% |
| 2023 Q1 | -316.21 Thousand EUR | 62.61% |
| 2023 Q4 | -374.34 Thousand EUR | -56.41% |
| 2023 Q3 | -239.33 Thousand EUR | 61.94% |
| 2023 FY | - EUR | 7.92% |
| 2022 Q1 | -585.56 Thousand EUR | -10.77% |
| 2022 Q3 | -348.45 Thousand EUR | 65.92% |
| 2022 Q4 | -845.66 Thousand EUR | -142.69% |
| 2022 FY | - EUR | -60.92% |
| 2022 Q2 | -1.02 Million EUR | -74.6% |
| 2021 Q1 | -378.51 Thousand EUR | 22.02% |
| 2021 Q3 | -206.79 Thousand EUR | 56.14% |
| 2021 Q2 | -471.5 Thousand EUR | -24.57% |
| 2021 FY | - EUR | -178.0% |
| 2021 Q4 | -528.63 Thousand EUR | -155.63% |
| 2020 Q4 | -485.41 Thousand EUR | -349.42% |
| 2020 Q3 | -108 Thousand EUR | 22.18% |
| 2020 Q2 | -138.79 Thousand EUR | -100.01% |
| 2020 FY | - EUR | -275.83% |
| 2020 Q1 | -69.39 Thousand EUR | 0.0% |
| 2019 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | 84.276% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 99.612% |
| Adocia SA | -22.73 Million EUR | 97.724% |
| Aelis Farma SA | -6.34 Million EUR | 91.849% |
| Biophytis S.A. | -13.8 Million EUR | 96.252% |
| Advicenne S.A. | -6.24 Million EUR | 91.715% |
| genOway Société anonyme | 6.35 Million EUR | 108.146% |
| IntegraGen SA | -52.5 Thousand EUR | -885.346% |
| Medesis Pharma S.A. | -3.84 Million EUR | 86.545% |
| Neovacs S.A. | -8.44 Million EUR | 93.877% |
| NFL Biosciences SA | -4.04 Million EUR | 87.224% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 813.272% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | 81.996% |
| Sensorion SA | -22.31 Million EUR | 97.682% |
| Theranexus Société Anonyme | -7.38 Million EUR | 92.997% |
| TME Pharma N.V. | -5.07 Million EUR | 89.8% |
| Valbiotis SA | -6.95 Million EUR | 92.562% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 97.265% |
| argenx SE | -199.5 Million EUR | 99.741% |
| BioSenic S.A. | -6.79 Million EUR | 92.388% |
| Celyad Oncology SA | -7.76 Million EUR | 93.336% |
| DBV Technologies S.A. | -79.53 Million EUR | 99.35% |
| Galapagos NV | 51.03 Million EUR | 101.014% |
| Genfit S.A. | -28.05 Million EUR | 98.156% |
| GeNeuro SA | -14.31 Million EUR | 96.387% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 96.546% |
| Innate Pharma S.A. | -7.57 Million EUR | 93.173% |
| Inventiva S.A. | -101.84 Million EUR | 99.492% |
| MaaT Pharma SA | -19.74 Million EUR | 97.379% |
| MedinCell S.A. | -20.04 Million EUR | 97.419% |
| Nanobiotix S.A. | -34.01 Million EUR | 98.479% |
| Onward Medical N.V. | -35.23 Million EUR | 98.532% |
| Oryzon Genomics S.A. | -4.43 Million EUR | 88.331% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 97.776% |
| Oxurion NV | -16.72 Million EUR | 96.908% |
| Pharming Group N.V. | 4.98 Million EUR | 110.386% |
| Poxel S.A. | -12.17 Million EUR | 95.752% |
| GenSight Biologics S.A. | -21.73 Million EUR | 97.619% |
| Transgene SA | -27.02 Million EUR | 98.086% |
| Financière de Tubize SA | 184.57 Thousand EUR | 380.291% |
| UCB SA | 1.26 Billion EUR | 100.041% |
| Valneva SE | -64.51 Million EUR | 99.198% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 98.175% |